Jagsonpal Pharmaceuticals offers to buyback up to 16 lakh equity shares (2.38% of capital) at ₹250 per share via tender offer route for an aggregate ₹40 crores.
Buyback opens May 8, 2026 and closes May 14, 2026, with record date set as May 4, 2026 for shareholder eligibility determination.
The offer includes 15% reservation for small shareholders and is funded from free reserves, aiming to enhance shareholder returns and improve ROCE by ~400 bps.
Promoters have expressed intention not to participate, and post-buyback promoter holding may increase from 67.71% to 69.36% assuming full acceptance.